Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Laura Borodyansky is active.

Publication


Featured researches published by Laura Borodyansky.


Apoptosis | 1998

Apoptosis in non-proliferating cells: implications for viral infection and tumourigenesis.

Laura Borodyansky; Youzhi Li; Arthur B. Pardee; Chiang Li

To date much attention has been focused on regulation of apoptosis in proliferating cells. However, recent evidence shows that regulation of apoptosis in quiescent tissue plays an important role in homeostasis of the organism. This review examines the implications of apoptosis of quiescent cells for both tumourigenesis and viral infection such as HIV. In this article we propose a dual role for cellular activation in the homeostasis regulation. In this model cellular mitogens not only activate quiescent cells into the active cell cycle, but under certain conditions, loss of quiescence may result in apoptosis. The loss of quiescence-associated apoptosis may play a significant role in tumourigenesis and viral infections.


Proceedings of the National Academy of Sciences of the United States of America | 1997

Tat protein induces self-perpetuating permissivity for productive HIV-1 infection

Chiang J. Li; Yutaka Ueda; Bin Shi; Laura Borodyansky; Lili Huang; Youzhi Li; Arthur B. Pardee


Journal of Clinical Oncology | 2016

The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.

Manish A. Shah; Kei Muro; Kohei Shitara; Niall C. Tebbutt; Yung-Jue Bang; Florian Lordick; Laura Borodyansky; Chiang Li


Journal of Clinical Oncology | 2017

A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).

Tanios Bekaii-Saab; Alexander Starodub; Bassel F. El-Rayes; Bert H. O'Neil; Safi Shahda; Kristen K. Ciombor; Anne M. Noonan; Wahid Tewfik Hanna; Amikar Sehdev; Walid Labib Shaib; Sameh Mikhail; Anterpreet S. Neki; Cindy Oh; Youzhi Li; Wei Li; Laura Borodyansky; Chiang Li


Journal of Clinical Oncology | 2017

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

Johanna C. Bendell; Bert H. O'Neil; Alexander Starodub; Derek J. Jonker; Thorvardur R. Halfdanarson; William Jeffery Edenfield; Bassel F. El-Rayes; Joleen M. Hubbard; Henry C. Pitot; Timothy J. Hobday; Youzhi Li; Yuan Gao; Axel Grothey; Laura Borodyansky; Chiang Li


Journal of Clinical Oncology | 2015

A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.

Kristen K. Ciombor; William Jeffery Edenfield; Joleen M. Hubbard; Peter J. O'Dwyer; Carlos Becerra; Timothy S. Larson; Alexander I. Spira; Axel Grothey; Divya Manoharan; Wei Li; Youzhi Li; Laura Borodyansky; Chiang Li; Tanios Bekaii-Saab


Journal of Clinical Oncology | 2017

Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

Johanna C. Bendell; Joleen M. Hubbard; Bert H. O'Neil; Derek J. Jonker; Alexander Starodub; James D. Peyton; Henry C. Pitot; Thorvardur R. Halfdanarson; Benjamin Rolland Nadeau; John D. Zubkus; Bamidele Adesunloye; William Jeffery Edenfield; Youzhi Li; Wei Li; Axel Grothey; Laura Borodyansky; Chiang Li


Journal of Clinical Oncology | 2017

BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer.

Timothy S. Larson; Waldo Feliu Ortuzar; Tanios Bekaii-Saab; Carlos Becerra; Kristen K. Ciombor; Joleen M. Hubbard; William Jeffery Edenfield; Spencer H. Shao; Axel Grothey; Laura Borodyansky; Bo Xu; Wei Li; Youzhi Li; Chiang Li; Waheed Khan


Journal of Clinical Oncology | 2016

Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).

Joleen M. Hubbard; Bert H. O'Neil; Derek J. Jonker; Thorvardur R. Halfdanarson; Alexander Starodub; Axel Grothey; Laura Borodyansky; Chiang Li


Journal of Clinical Oncology | 2017

CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).

Axel Grothey; Manish A. Shah; Takayuki Yoshino; Eric Van Cutsem; Julien Taieb; Rui-hua Xu; Niall C. Tebbutt; Alfredo Falcone; A. Cervantes; Laura Borodyansky; Chiang Li

Collaboration


Dive into the Laura Borodyansky's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge